Cisplatin + nintedanib + pemetrexed + placebo

WebOther strategies to target VEGF have included the use of the angiokinase inhibitor nintedanib in combination with cisplatin and pemetrexed chemotherapy in the Phase III, randomised LUME-Meso trial. 40 This failed to demonstrate a benefit for median PFS for the addition of nintedanib (6.8 versus 7.0 months, HR 1.01 95% CI 0.79–1.30, p = 0.914). WebMay 15, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural …

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous …

WebPatients received oral nintedanib (150 mg or 200 mg twice daily for 12 weeks) or placebo, in addition to usual neoadjuvant chemotherapy with intravenous gemcitabine 1000 mg/m 2 on days 1 and 8 and intravenous cisplatin 70 mg/m 2 on day 1 of a 3-weekly cycle. The primary endpoint was pathological complete response rate, assessed at cystectomy or ... WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … how many planets in the imperium of man https://bowlerarcsteelworx.com

Efficacy of chemotherapy for malignant pleural mesothelioma …

WebThis study enrolled 87 participants with chemo-naïve unresectable MPM, ECOG performance status 0–1, and non-sarcomatoid disease histology. Patients were randomized 1:1, double blinded, to cisplatin/pemetrexed with nintedanib 200 mg b.d. or placebo, and nintedanib or placebo was subsequently continued as monotherapy until progression. WebDec 19, 2016 · ITT analysis of the primary end point showed that treatment with nintedanib plus pemetrexed resulted in a significant prolongation of PFS compared with placebo plus pemetrexed (4.4 vs. 3.6 months with a HR of 0.83 and a p value of 0.04). WebJ Clin Oncol 31(23):2895–2902 CrossRef Paz-Ares LG et al (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. how many planets in the andromeda galaxy

LUME-Meso: Design and Rationale of the Phase III Part of …

Category:Addition of nintedanib or placebo to neoadjuvant gemcitabine …

Tags:Cisplatin + nintedanib + pemetrexed + placebo

Cisplatin + nintedanib + pemetrexed + placebo

Bronchuskarzinom Medizinische Leitlinie - Tumorzentrum

WebMay 30, 2024 · Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Anna K. Nowak. x. Anna K. Nowak. Search for articles by this author , Federica Grosso. x ... WebDec 9, 2024 · Scagliotti GV, et al. Nintedanib in Combination with Pemetrexed and Cisplatin for Chemotherapy-Naive Patients with Advanced Malignant Pleural …

Cisplatin + nintedanib + pemetrexed + placebo

Did you know?

WebJul 24, 2013 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … WebApr 1, 2024 · Request PDF On Apr 1, 2024, Antoinette J. Wozniak and others published Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) Find, read and cite all ...

WebMay 15, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME … WebJul 5, 2024 · Nintedanib, oral, triple angiokinase inhibitor of VEGFR, PDGFR, and FGFR, has been investigated in a phase II study randomizing patients who received first line pemetrexed-cisplatin between nintedanib or placebo. Recently, preliminary data were reported on the additional effect of nintedanib added to cisplatin/pemetrexed.

WebThe pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) c… WebNintedanib is an oral angiokinase inhibitor targeting multiple signaling pathways implicated in the pathogenesis of MPM, including the VEGF receptor. The phase III part of the …

WebSep 11, 2024 · Treatment with pemetrexed and cisplatin and either nintedanib or matching placebo was given in 21-day courses. …

WebApr 11, 2024 · Nintedanib doses were permitted to be reduced to 150 mg, 100 mg, or 50 mg (or to 100 mg or 50 mg for patients with GFR 40–60 mL/min). Both gemcitabine and … how many planets in our galaxy may have lifeWebOct 15, 2024 · which tested the addition of nintedanib to pemetrexed and cisplatin in 87 patients with unresectable malignant pleural mesothelioma with epithelioid and biphasic histology, reported an overall survival of 14·2 months (95% CI 12·3–20·9) in the control group and 18·3 months (15·2–28·8) in the experimental group. how clear notificationsWebThe intervention group received up to six cycles of pemetrexed and cisplatin plus nintedanib 200 mg twice daily while the control group received chemotherapy plus … how clear search barWebPatients were randomly assigned in a 1:1 ratio to receive nintedanib or placebo. Randomization was stratified by histology (epithelioid or biphasic). Treatment with … howclear rower cashceWebOct 1, 2024 · PDF On Oct 1, 2024, Federica Grosso and others published SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial Find ... how clear python shellWebApr 7, 2024 · This is a Phase II trial assessing the efficacy of nintedanib, an oral multi-targeted kinase inhibitor, in patients with recurrent malignant pleural mesothelioma. The drug was well tolerated but the activity was modest with no responses and 40% stable disease at 8 weeks. how many planets in the solarWebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … how clear search